G. Krystal

发表

Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction.

S. Grant, J. Litz, P. Carlson, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A novel assay for the measurement of Raf-1 kinase activity

S. Grant, G. Krystal, C. Bondzi, 2000, Oncogene.

Imatinib mesylate (STI571) for myeloid malignancies other than CML.

G. Krystal, Geoffrey W Krystal, 2004, Leukemia research.

Small cell carcinomas of the lung express the Bcl-2 protein.

J. Ben-Ezra, G. Krystal, M. Grimes, 1994, The American journal of pathology.

The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.

F. Hofmann, E. Buchdunger, C. García-echeverría, 2004, Molecular cancer therapeutics.

Early FDG/PET Scanning as a Pharmacodynamic Marker of Anti-EGFR Antibody Activity in Colorectal Cancer

G. Krystal, J. Tatum, E. Alesi, 2012, Molecular Cancer Therapeutics.

Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer

H. Harada, G. Krystal, W. Nakajima, 2016, Cancer biology & therapy.

Clinical Cancer esearch cer Therapy : Preclinical inomycin D Decreases Mcl-1 Expression and Acts ergistically with ABT-737 against Small Cell R g Cancer Cell Lines

G. Krystal, Haishan Xu, Syn Lun, 2010 .

Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737

J. Litz, G. Krystal, B. Chao, 2009, Molecular Cancer Therapeutics.

Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.

D. Ludwig, J. Litz, G. Krystal, 2007, Lung cancer.

Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancer

J. Battey, E. Sausville, J. Minna, 1988, Molecular and cellular biology.

Short Communication Activating c-kit Gene Mutations in Human Germ Cell Tumors

C. Moskaluk, H. Frierson, G. Krystal, 1999 .

Selective digestion of mouse metaphase chromosomes

B. Hamkalo, J. B. Rattner, G. Krystal, 1978, Chromosoma.

Secretion of a unique peptide from interleukin-2-stimulated natural killer cells that induces endomitosis in immature human megakaryocytes.

G. Krystal, E. Dessypris, P. Angchaisuksiri, 2002, Blood.

Phosphorylation of cleavage stage histone H1 in mitotic and prematurely condensed chromosomes.

G. Krystal, D. Poccia, 1981, Experimental cell research.

Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737

G. Krystal, 2010, Cancer biology & therapy.

Multiple Mechanisms forTranscriptional Regulation ofthemyc GeneFamily inSmall-Cell LungCancer

E. Sausville, J. Minna, M. Nau, 1988 .

Comparison of c-, N-, and L-myc transcriptional regulation.

J. Battey, G. Krystal, J. Way, 1988, Current topics in microbiology and immunology.

G. Krystal, Haish, 2010 .

Clinical Cancer esearch cer Therapy : Preclinical inomycin D Decreases Mcl-1 Expression and Acts ergistically with ABT-737 against Small Cell R g Cancer Cell Lines

G. Krystal, S. Lun, Syn Lun, 2010 .

Identification of novel human tumor cell-specific CaMK-II variants.

G. Krystal, R. Tombes, 1997, Biochimica et biophysica acta.

Transitions in histone variants of the male pronucleus following fertilization and evidence for a maternal store of cleavage-stage histones in the sera urchin egg.

G. Krystal, D. Poccia, J. Salik, 1981, Developmental biology.

Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1α activity and vascular endothelial growth factor expression in small cell lung cancer cells

J. Litz, G. Krystal, 2006, Molecular Cancer Therapeutics.

The expression of stem cell factor and its receptor, c-kit in human endometrium and placental tissues during pregnancy.

J. Ryan, G. Krystal, P. Takacs, 1996, The Journal of clinical endocrinology and metabolism.

Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer.

F. Khuri, S. Sebti, C. Arteaga, 2002, Seminars in oncology.

Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.

G. Krystal, S. Hines, C. Organ, 1996, Cancer research.

Coexpression of the c-kit and stem cell factor genes in breast carcinomas.

G. Krystal, M. Kornstein, S. Hines, 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Activating c-kit gene mutations in human germ cell tumors.

C. Moskaluk, H. Frierson, G. Krystal, 1999, The American journal of pathology.

Partial purification and characterization of the intercellular bridge from cultured mouse cells.

B. Hamkalo, J. B. Rattner, G. Krystal, 1978, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.

J. Litz, G. Krystal, Geoffrey Sulanke, 2002, Molecular cancer therapeutics.

The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.

S. Honsawek, E. Buchdunger, J. Litz, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Isolation and characterization of complementary DNA for N-cym, a gene encoded by the DNA strand opposite to N-myc.

G. Krystal, B. C. Armstrong, Barbara C. Armstrong, 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines.

P. Carlson, G. Krystal, H. Plummer, 1993, Cancer research.

Transcriptional activation and DNase I hypersensitive sites are associated with selective expression of the gastrin-releasing peptide gene.

J. Battey, E. Sausville, G. Krystal, 1988, The Journal of clinical investigation.

N-myc mRNA forms an RNA-RNA duplex with endogenous antisense transcripts

J. Battey, G. Krystal, Barbara Armstrong, 1990, Molecular and cellular biology.

Selective Sp1 binding is critical for maximal activity of the human c-kit promoter.

G. Krystal, H. Plummer, G. Park, 1998, Blood.

CONTROL OF SPERM CHROMATIN STRUCTURE BY EGG CYTOPLASM IN THE SEA URCHIN

G. Krystal, D. Poccia, D. Nishioka, 1978 .

Role of small-molecule kit receptor tyrosine kinase inhibitors in the treatment of small-cell lung cancer.

G. Krystal, K. Lloyd, 2002, Clinical lung cancer.

Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.

S. Honsawek, G. Mcmahon, L. Sun, 2001, Cancer research.

Growth of Small Cell Lung Cancer Cells Indolinone Tyrosine Kinase Inhibitors Block Kit Activation and Updated

S. Honsawek, G. Mcmahon, C. Liang, 2001 .

Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer.

J. Massagué, A. Chiang, P. Wipf, 2007, Nature chemical biology.

The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy

F. Hofmann, E. Buchdunger, C. García-echeverría, 2005, Clinical Cancer Research.

Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes.

J. Grandis, P. Dent, A. Yacoub, 2005, Biochemical pharmacology.

Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression

Krista M. Powell, Patricia Greninger, C. Benes, 2017, Clinical Cancer Research.

In Breast Carcinomas

G. Krystal, C. Organ, 1995 .

Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents.

G. Krystal, 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Coexpression of c-kit and stem cell factor in breast cancer results in enhanced sensitivity to members of the EGF family of growth factors

J. Litz, G. Krystal, S. Hines, 1999, Breast Cancer Research and Treatment.

Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.

J. Litz, G. Krystal, G W Krystal, 1998, Cancer research.

Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins.

J. Litz, P. Carlson, G. Krystal, 1997, Cancer research.

Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo

G. Krystal, D. Rodrı́guez-Agudo, W. Pandak, 2015, Oncotarget.

The rat prepro gastrin releasing peptide gene is transcribed from two initiation sites in the brain.

J. Battey, O. Sartor, G. Krystal, 1988, Molecular endocrinology.

Control of chromosome condensation in the sea urchin egg.

G. Krystal, D. Poccia, 1979, Experimental cell research.

Lines Protooncogene Expression in Small Cell Lung Cancer Cell kit Expression Correlates with Suppression of c-myc c-Updated

Joseph, G. Krystal, H. Plummer, 2006 .

Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells.

P. Dent, G. Krystal, J. Litz, 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Expression of the gastrin-releasing peptide gene in human small cell lung cancer. Evidence for alternative processing resulting in three distinct mRNAs.

J. Battey, E. Sausville, A. Gazdar, 1986, The Journal of biological chemistry.

The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.

J. Litz, G. Krystal, K. Lipson, 2004, Lung cancer.

Early FDG/PET Scanning as a Pharmacodynamic Marker of Anti-EGFR Antibody Activity in Colorectal Cancer

G. Krystal, J. Tatum, E. Alesi, 2012, Molecular Cancer Therapeutics.

Receptor tyrosine kinase mutations: Molecular indicators for therapeutic response or signposts marking important signaling pathways?

G. Krystal, 2005, Cancer biology & therapy.